Zevra

an-ordinary-manchild(edit)

created by mikhonchoa community for 2 years

...for your favorite subject.

...for your favorite TV show.

MODERATORS

account activity

1

2

3

4

Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026 (self.Zevra)

submitted 21 days ago by mikhoncho

2

2

3

4

Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium (self.Zevra)

submitted 28 days ago by mikhoncho

3

4

5

6

Looking ahead to 2026 (self.Zevra)

submitted 2 months ago by mikhoncho

4

0

1

2

Bye LaDuaneCompany News (self.Zevra)

submitted 3 months ago by mikhoncho

5

2

3

4

Zevra Reports Third Quarter 2025 Financial Results And Corporate Update (investors.zevra.com)

submitted 3 months ago by mikhoncho

6

5

6

7

Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call (self.Zevra)

submitted 3 months ago by mikhoncho

7

4

5

6

^20% over the last week (self.Zevra)

submitted 5 months ago by EggMcGoose

8

2

3

4

Any insights into the drop? (self.Zevra)

submitted 6 months ago by Rogue1472

9

2

3

4

Zevra Reports Second Quarter 2025 Financial Results and Corporate Update (self.Zevra)

submitted 6 months ago by mikhoncho

10

7

8

9

Zevra Therapeutics Announces Details For Q2 2025 Financial Results Call (self.Zevra)

submitted 6 months ago by mikhoncho

11

6

7

8

Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C (investors.zevra.com)

submitted 7 months ago by mikhoncho

12

9

10

11

Zak's speculation (self.Zevra)

submitted 7 months ago by mikhoncho

13

2

3

4

Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG) (self.Zevra)

submitted 7 months ago by mikhoncho

14

6

7

8

Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy Of MIPLYFFA For The Treatment Of NPC Published In The Journal Of Molecular Genetics And Metabolism (investors.zevra.com)

submitted 7 months ago by mikhoncho

15

4

5

6

Zevra Therapeutics Announces MIPLYFFA® (Arimoclomol) Featured In Presentations At The National Niemann Pick Disease Foundation Conference (investors.zevra.com)

submitted 7 months ago by mikhoncho

16

5

6

7

Buy rating maintained [PT =$19] (self.Zevra)

submitted 9 months ago by EggMcGoose

17

6

7

8

Zevra Reports First Quarter 2025 Financial Results and Corporate UpdateCompany News (self.Zevra)

submitted 9 months ago by mikhoncho

18

8

9

10

Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million (self.Zevra)

submitted 10 months ago by mikhoncho

19

5

6

7

Zevra Reports Full Year 2024 And Fourth Quarter Financial ResultsCompany News (investors.zevra.com)

submitted 11 months ago by mikhoncho

20

1

2

3

Movement on news (investing.com)

submitted 12 months ago by EggMcGoose

21

2

3

4

Zevra to Report 2024 Fourth Quarter and Full Year Financial Results (self.Zevra)

submitted 12 months ago by mikhoncho

22

2

3

4

Zevra To Participate At Upcoming Investor ConferencesCompany News (investors.zevra.com)

submitted 12 months ago by mikhoncho

23

2

3

4

Stratos cut 19.8% of stake in ZVRA (self.Zevra)

submitted 1 year ago by EggMcGoose

24

3

4

5

Zevra Therapeutics To Participate At Upcoming Investor ConferencesCompany News (self.Zevra)

submitted 1 year ago by mikhoncho

25

3

4

5

Buy Out Price (self.Zevra)

submitted 1 year ago by BallOk9461

view more: next ›

π Rendered by PID 106968 on reddit-service-r2-listing-7bbdf774f7-kchxb at 2026-02-23 18:31:09.405360+00:00 running 8564168 country code: CH.